Choroidal proteins involved in cerebrospinal fluid production may be potential drug targets for alzheimer's disease therapy

Perspectives in Medicinal Chemistry

Volumn 2011, Issue 5, 2011, Pages 11-17

  Wostyn, Peter ^a   Audenaert, Kurt ^b   De Deyn, Peter Paul ^c,d  

^a PC Sint Amandus ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; Aquaporin 1; Caffeine; Carbonic anhydrase ii; Cerebrospinal fluid pressure; Cerebrospinal fluid production; Choroid plexus; Intracranial pressure; Na+ K+ ATPase; SLC4a10

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMYLOID BETA PROTEIN; AQUAPORIN 1; BRAIN PROTEIN; CAFFEINE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CITALOPRAM; FLUOXETINE; SERTRALINE; SOLUTE CARRIER FAMILY 4 SODIUM BICARBONATE TRANSPORTER MEMBER 10; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBROSPINAL FLUID FLOW; CEREBROSPINAL FLUID PRESSURE; CHOROID PLEXUS; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME MECHANISM; HUMAN; MOLECULAR DYNAMICS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79952721876     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.4137/PMC.S6509     Document Type: Article

References (37)

1. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. Clin Neurol Neurosurg. 2008;110:101-109.
2. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease and glaucoma: Is there a causal relationship? Br J Ophthalmol. 2009;93:1557-1559.
3. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010;26:84-93.
4. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal- pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003;2:506-511.
5. Silverberg GD. Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both. Brain. 2004;127:947-948.
6. Silverberg GD, Huhn S, Jaffe RA, et al. Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus. J Neurosurg. 2002;97:1271-1275.
7. Silverberg G, Mayo M, Saul T, Fellmann J, McGuire D. Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease. Cerebrospinal Fluid Res. 2006;3:7.
8. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology. 2001;57:1763-1766.
9. Silverberg GD, Levinthal E, Sullivan EV, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology. 2002;59:1139-145.
10. Klinge PM, Samii A, Mühlendyck A, et al. Cerebral hypoperfusion and delayed hippocampal response after induction of adult kaolin hydrocephalus. Stroke. 2003;34:193-199.
11. Wostyn P, Audenaert K, De Deyn PP. More advanced Alzheimer's disease may be associated with a decrease in cerebrospinal fluid pressure. Cerebrospinal Fluid Res. 2009;6:14.
12. Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology. 2008;71:202-209.
13. Serot JM, Bene MC, Faure GC. Normal-pressure hydrocephalus and Alzheimer disease. J Neurosurg. 2003;99:797-798; author reply 798-799.
14. Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129:957-970.
15. Serot JM, Bene MC, Foliguet B, Faure GC. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol (Berl). 2000;99:105-108.
16. Serot JM, Bene MC, Faure GC. Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci. 2003;8:s515-521.
17. Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:10.
18. Han ME, Kim HJ, Lee YS, et al. Regulation of cerebrospinal fluid production by caffeine consumption. BMC Neurosci. 2009;10:110.
19. Liu W, Liu Y, Qin XJ, Schmidt S, Hauser MA, Allingham RR. AQP1 and SLC4A10 as candidate genes for primary open-angle glaucoma. Mol Vis. 2010;16:93-97.
20. Richards KS, Bommert K, Szabo G, Miles R. Differential expression of Na+/K+-ATPase alpha-subunits in mouse hippocampal interneurones and pyramidal cells. J Physiol. 2007;585:491-505.
21. Chen X, Ghribi O, Geiger JD. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis. 2010;20:127-141.
22. Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain betaamyloid production. Neuroscience. 2006;142:941-952.
23. Maia L, de Mendonça A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol. 2002;9:377-382.
24. Cao C, Cirrito JR, Lin X, et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis. 2009;17:681-697.
25. Arendash GW, Mori T, Cao C, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis. 2009;17:661-680.
26. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol. 2006;545:39-50.
27. Sun MK, Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol Sci. 2002;23:83-89.
28. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr. 1984;3:161-165.
29. Casini A, Caccia S, Scozzafava A, Supuran CT. Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II. Bioorg Med Chem Lett. 2003;13:2765-2768.
30. Masseguin C, LePanse S, Corman B, Verbavatz JM, Gabrion J. Aging affects choroidal proteins involved in CSF production in Sprague-Dawley rats. Neurobiol Aging. 2005;26:917-927.
31. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168-181.
32. Sun MK, Alkon DL. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J Pharmacol Exp Ther. 2001;297:961-967.
33. Gurnett CA, Veile R, Zempel J, Blackburn L, Lovett M, Bowcock A. Disruption of sodium bicarbonate transporter SLC4A10 in a patient with complex partial epilepsy and mental retardation. Arch Neurol. 2008;65: 550-553.
34. Jacobs S, Ruusuvuori E, Sipilä ST, et al. Mice with targeted Slc4a10 gene disruption have small brain ventricles and show reduced neuronal excitability. Proc Natl Acad Sci U S A. 2008;105:311-316.
35. Boassa D, Stamer WD, Yool AJ. Ion channel function of aquaporin-1 natively expressed in choroid plexus. J Neurosci. 2006;26:7811-7819.
36. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroids plexus water channel Aquaporin-1. FASEB J. 2005;19:76-78.
37. Yool AJ. Aquaporins: multiple roles in the central nervous system. Neuroscientist. 2007;13:470-478